市場調査レポート

ドラッグデリバリー(薬剤送達)部門におけるナノテクノロジーの利用:2011-2021年

Nanotechnology in Drug Delivery 2011 - 2021

発行 Cientifica Ltd 商品コード 221349
出版日 ページ情報 英文 212 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
ドラッグデリバリー(薬剤送達)部門におけるナノテクノロジーの利用:2011-2021年 Nanotechnology in Drug Delivery 2011 - 2021
出版日: 2011年10月31日 ページ情報: 英文 212 Pages
概要

医療部門はナノテクノロジーの恩恵をもっとも早く受けられる市場であると位置付けられており、今後10年でもっとも高い成長率を記録するエンドユーズ部門となる見通しです。ナノテクノロジーの応用によるメリットを受けられる分野としては、癌治療のための標的ドラッグデリバリー(薬剤送達)がもっとも広く認識されています。ナノテクドラッグデリバリーの有効市場は2010年から2021年まで49.96%の年平均成長率で推移し、2021年には1,361億3,400万米ドルの市場規模に達すると予測されています。

当レポートでは、世界の主要地域におけるナノテクドラッグデリバリーの発展動向について調査分析し、ナノテクノロジーの概要、医学・生体医学部門へのナノテクノロジーの応用とその重要性、メリット、導入推進因子、ドラッグデリバリー部門での応用例と開発ステージ、臨床承認済みのナノキャリア・ナノ結晶製剤、技術導入のロードマップ、有効市場の市場規模予測(〜2021年)などをまとめ、概略下記の内容でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション・調査手法

第2章 イントロダクション:ナノテクノロジーと医療

  • ナノテクノロジー:概要
    • 医学・生体医学部門における重要性
    • 医学・生体医学部門でのニーズ
  • ナノテクノロジーの医学・生体医学部門への導入推進因子
    • ナノ粒子ドラッグデリバリーの導入推進因子
    • 高齢者人口の増大
    • より低価格な医療への需要
    • 公共医療
    • 革新へのニーズ
    • 社会的責任
  • 医学・生体医学部門においてもっとも重要なナノテクノロジー導入分野
    • ドラッグデリバリー
    • 医学・生物医学的診断
    • 再生医療・再生医学
    • 医療・医薬品部門におけるその他の適用分野
  • ナノテクノロジーのドラッグデリバリー部門への影響
    • ケーススタディ

第3章 医学・生体医学部門へのナノテクノロジーの導入:主な阻害因子

  • 医学・生体医学部門へのナノテクノロジーの導入:主な阻害因子
    • ナノ毒性・ナノ汚染・ナノセーフティ
    • ナノ治療の倫理的考察
    • ナノ関連規制の整備の遅れ
  • 医学・生体医学部門へのナノテクノロジーの導入:現在および将来の課題
    • ナノセーフティとリスクマネジメント
    • ナノ関連規制
    • ナノ医療産業
    • 革新の持続
    • 提携・協力
  • 市場分析(2000-2010年)
  • 市場予測(〜2021年)

第4章 ドラッグデリバリー部門におけるナノテクノロジー

  • ドラッグデリバリー部門で利用される主要ナノテクノロジー
    • ナノ医薬品
    • ドラッグデリバリーにおけるナノテクノロジー
    • ドラッグデリバリーにおけるナノバイオテクノロジー
    • ナノ粒子ドラッグデリバリーのための解析技術
    • ナノキャリア
    • ナノテクノロジーベースのナノキャリアの代替品
    • 最重要技術
  • ドラッグデリバリー部門で利用される主要ナノテクノロジーの開発ステージ
    • 上市されている臨床承認済みナノキャリア製剤
    • 上市されている臨床承認済みナノ結晶製剤
    • 現在および将来のアプリケーション
    • 市場分析:市場区分別
  • 技術導入ロードマップ
    • 製品開発予測:ナノキャリアベースの製剤
    • 製品開発予測:ナノ結晶ベースの製剤
    • 市場予測:市場区分別(〜2021年)
    • SWOT分析(2011-2021年)

図表

目次
Product Code: CIEN2011NDD

Abstract

The healthcare market is poised to see some of the earliest benefits of nanotechnology. Over the next decade, it will be one of nanotech's highest growth sectors. Targeted drug delivery therapies for the treatment of cancer is one of the most commonly cited nano-healthcare benefits. Cientifica's report, Nanotechnology in Drug Delivery 2011, gives a comprehensive analysis and geographic breakdown of the current nanotechnology drug delivery market and its most relevant technologies. It also provides a forecast for the size of total addressable markets and percent share of those key technologies to 2021.

Some forecasts have predicted the nanotechnology market to reach close to a trillion dollars by 2015, presenting investors with unique opportunities. However, the market for applications of nanotechnology is complex, multidisciplinary and highly segmented. It is therefore essential to gain an understanding of which market sectors nanotechnology is likely to impact most profoundly in the near term.

Since we now know most (if not all) biological processes occur at the nanoscale, the application of life science principles - studying the causes of biological phenomena at the molecular level - means medical and biomedical research is increasingly using a bottom-up (rather than the top-down) approach. The low bioavailability resulting from traditional oral and intravenous drug delivery methods and the market forces at work in the pharmaceutical industry, where patents expire after a relatively short period of time unless a novel form of drug delivery is developed that will extend the patent, are two major forces that will fuel the growth of the nanotech drug delivery market. The third factor at play is a combination of improved global health and a correspondingly dramatic increase in the size of the global aging population.

This report provides insight into the possibilities of targeted nanotech drug delivery and its market potential over the next decade.

Market Scope

This report provides an in-depth presentation of recent developments in nanotech drug delivery (NDD) and provides market opportunities to 2021, for the largest economies in the Americas, Asia, Europe and the rest of the world. Two market analyses are presented;

  • The historical market growth for NDD between 2000-2010
  • Market forecast for NDD from 2011 to 2021

Both sets of data are segmented into market by geographical region (US$ millions, % share, and compound annual growth rates by country) for America; Asia, Europe, and Rest of the World (key economies only) and by technology type (US$ millions, percent share and compound annual growth rate). Technology types examined include:

  • Solubility & Bioavailability
  • Targeted Delivery
  • Drug Nanocrystals
  • Total Nanocarriers
  • Liposomes
  • Carbon nanotubes
  • Gold Nanocarriers
  • Dendrimers
  • Micelles
  • Polymer-based Nanocarriers
  • Nanoshells
  • Ceramic Nanocarriers
  • Calcium phosphate Nanocarriers

Summary of findings (current and future)

The market growth for NDD in the period 2000-2010 shows it reached US$1,030 million by 2010.

image1

The forecast for nanotech drug delivery to 2021 shows that the total addressable market will reach US$ 136,134 million by 2021 and the compound annual growth rate (CAGR) is estimated to be 49.96% over the period 2010-20121.

Also included in the report is:

  • An overview of nanotechnology;
  • Identification of several key drivers for nanotechnology adoption in medicine and biomedicine;
  • The most important fields for the adoption of nanotechnology in medicine; and
  • An explanation of how nanotechnology is already having an impact on the drugs delivery sector through several relevant case studies.

In addition to an examination of general trends, Nanotechnology in Drug Delivery 2011 identifies five current & future challenges to as well as the major barriers to adoption of nanotechnology in medicine and biomedicine and provides a Technology Adoption Roadmap.

The report examines the stage of development of key nanotechnologies used in drug delivery, sorted by applications, including

  • Nanopharmaceuticals
  • Nanobiotechnology in drug delivery
  • Analytical techniques for nanoparticle drug delivery
  • Clinically approved nanocarrier-based formulations present on the market and in the pipeline
  • Clinically approved nanocrystals-based formulations present on the market and in development
  • Nanotechnology-based alternatives to nanocarriers in drug delivery
  • Present and future applications

Methodology

Information contained within this report is procured from several sources. These include proprietary research carried out by Cientifica, primary sources including interviews with industry and academics, and secondary sources including online publications and datasets to determine:

  • current size of pharma, drug delivery and nanotech drug delivery markets including compound annual growth rates (CAGR)
  • population sizes/growth to 2021
  • global and regional health statistics
  • patent data including expiration dates
  • pharma company mergers and acquisitions
  • company and university R&D expenditure
  • trends in governments' healthcare spending figures including CAGR
  • current drug delivery market as percent of whole pharma market including CAGR
  • highest grossing drug delivery products currently on the market
  • drug delivery research and publication statistics.

This data is analysed to provide the current nanotech drug delivery market (2010) and global total addressable market for products for the next decade.

Table of Contents

Table of Exhibits

Executive Summary

Chapter 1

  • Introduction and Methodology
  • Report Scope
    • Thematic Scope
    • Scope of Data Analysis
    • Temporal Scope of Analysis
    • Geographical Scope
  • Report objective
  • Methodology
    • Cientifica, Ltd Nanotechnology Model
    • Major Assumptions
    • Market Values And Publishing Activity
    • Publishing Activity And TAM (2000-2010 period)
    • Calculation of CAGR
    • The Nanoscale

Chapter 2

  • Introduction to Nanotechnology & Medicine
  • Overview of nanotechnology
    • Why is Nanotechnology A Critical Application for Medicine and Biomedicine?
    • Why Nanotechnology Is Needed for Medicine and Biomedicine?
  • What are the Key Drivers for Adoption of Nanotechnology in Medicine and
  • Biomedicine?
    • Drivers For Nanoparticle Drug Delivery
      • THE AIM OF DRUG TARGETING
      • REASONS WHY THE DRUG DELIVERY MARKET IS RAPIDLY EXPANDING
      • MARKET DRIVERS FOR ENHANCED DRUG DELIVERY
    • Increasing Proportion of The Aging Population
    • Demand More Affordable Health Care
    • Public Health - Ending disease
    • Demand for More Innovation
    • Social responsibility
  • The Most Important Fields in The Adoption of Nanotechnology in Medicine and Biomedicine
    • Nanotechnology in Drug Delivery
    • Nanotechnology in Medical and Biomedical Diagnostics
    • Nanotechnology in Regenerative Medicine and Tissue Engineering
    • Other Applications For Nanomaterials In The Medical And Pharmaceutical Sector
  • How Nanotechnology is Already Having an Impact on The Drug Delivery Sector
    • Case Study 1 - Magnetic Field Acts as "Remote Control" to Deliver Nanomedicine
    • Case Study 2 - Adaptive Micro and Nanoparticles: Temporal Control Over Carrier
    • Properties to Facilitate Drug Delivery
    • Case Study 3 - Fabrication of a Nanocarrier System Through Self-Assembly of
    • Plasma Protein And Its Tumour Targeting
    • Case Study 4 - IBM And The Institute of Bioengineering and Nanotechnology
    • Find Breakthrough For MRSA Treatment - New Molecular Structures Could Fight
    • Infectious Diseases Better Than Conventional Antibiotics
    • References

Chapter 3

  • Key Barriers to The Adoption of Nanotechnology in Medicine and Biomedicine
    • Nanotoxicity Nanopollution and Nanosafety
    • Ethical considerations of nanotherapies
    • Delayed Nanoregulation
  • Current & Future Challenges of The Adoption of Nanotechnology in Medicine and Biomedicine
    • Current & Future Challenges of Nanosafety And Risk Management
    • Current & Future Challenges of Nanoregulation
    • Current & Future Challenges of Nanomedicine Industry
    • Current & Future Challenges of Sustained Innovation
    • Current & Future Challenges of Cooperation
  • Market Analysis (2000-2010) Without Segmentation
  • Market Forecast to 2021 Without Segmentation
  • References

Chapter 4

  • Nanotechnology in Drug Delivery
  • Overview of The Key Nanotechnologies Used in Drug Delivery Sorted by
  • Applications
    • Nanopharmaceuticals
    • Nanotechnology In Drug Delivery
    • Nanobiotechnology In Drug Delivery
    • Analytical Techniques For Nanoparticle Drug Delivery
      • PROPERTIES
      • PRODUCTION OF NANOPARTICLES
      • MEASURING DISPERSION OF NANOPARTICLES
      • ANALYSIS OF CARRIER SYSTEMS
    • Nanocarriers
      • CLASSIFICATION OF NANOCARRIERS
      • MULTIFUNCTIONAL NANOCARRIERS - DRUG DELIVERY AND
    • MEDICAL/BIOMEDICAL DIAGNOSTICS
      • NANOCARRIERS AS DRUG CARRIERS
      • WHAT CAN NANOPARTICLES DO IN DRUG DELIVERY?
      • POLYMER-BASED NANOCARRIERS (POLYMERIC NANOPARTICLES)
      • LIPID-BASED NANOCARRIERS
      • ORGANIC NANOCARRIERS
      • INORGANIC NANOCARRIERS
      • DISADVANTAGES ASSOCIATED WITH NANOCARRIERS
    • Nanotechnology-Based Alternatives to Nanocarriers in Drug Delivery
      • DRUG NANOCRYSTALS: NANOSIZING THE DRUGS
    • The Most Relevant Key Technologies in The Key Area of Nanotechnology in Drug Delivery
  • Stage of Development of Key Nanotechnologies Used in Drug Delivery
    • Clinically Approved Nanocarrier-Based Formulations With Presence in The Market
      • THE FIRST NANOPARTICLE DRUG DELIVERY SYSTEM REACHES THE MARKET
    • Clinically Approved Nanocrystals-Based Formulations With Presence in the Market
    • Present And Future Applications
    • Market Analysis With Segmentation
      • MARKET BY COUNTRY (2000-2010)
      • MARKET BY KEY TECHNOLOGY (2000-2010)
  • Technology Adoption Roadmap
    • Projected Product Pipeline For Nanocarrier-Based Drug Formulations In Drug Delivery Market
      • OVERVIEW OF NANOPARTICLE DRUG DELIVERY SYSTEM (DDS) IN VARIOUS APPLICATIONS
      • AVAILABLE APPLICATIONS OF NANOPARTCILE IN DRUG DELIVERY
    • Projected Product Pipeline For Nanocrystals-Based Drug Formulations In Drug Delivery Market;
      • SEMAPIMODR (CYTOKINE, PHARMASCIENCES)
      • PAXCEED"!
      • THERALUX"!
      • NUCRYSTR
    • Market Forecast to 2021, With Segmentation
      • MARKET FORECAST BY COUNTRY BY 2021
      • MARKET FORECAST BY KEY TECHNOLOGY BY 2021
    • SWOT Analysis (2011-2021 period)
    • References

Table of Exhibits

Chapter One. Introduction and Methodology

  • Exhibit 1.1
    • Formula for the calculation of the Compound Annual Growth Rate (CAGR), (top).
    • Formula for the calculation of the Compound Annual Growth Rate (CAGR) in this report, for the 2011-2021 period, (bottom) [2].
  • Exhibit 1.2
    • Formula for the verification of the calculated values of the Compound Annual Growth Rate (CAGR), (top).
    • Formula for the verification of the calculated values of the Compound Annual Growth Rate (CAGR) in this report, for the 2011-2021 period, (bottom) [2].
  • Exhibit 1.3
    • The equivalence between 1 nm in meter (top). The equivalence between 1 meter in nanometre (bottom).

Chapter Two: Introduction to Nanotechnology & Medicine

  • Exhibit 2.1
    • Illustration of the fact that the periodic table of elements, as we know it (at meter scale) governed by classic Newtonian laws of physics. However, when perceived at nanoscale, those elements are governed by the laws of quantum physics.
  • Exhibit 2.2
    • Proportion of the population aged over 65 and over 80 [7].
  • Exhibit 2.3
    • Illustration of a diagram of each property of nanocarriers (size, shape, surface chemistry and mechanical properties) and their parameters subjected to optimization in order to improve their efficiency [10].

Chapter Three: Technology Adoption Roadmap

  • Exhibit 3.1
    • Specified expected barriers in the development of particular types of nanoparticles (Courtesy of CienNanoroadmap Synthesis Report), [6].
  • Exhibit 3.2
    • Illustration of the measures adoption roadmap to combat/attenuate the key barriers to the adoption of nanotechnology in medicine and biomedicine (Source: Cientifica, Ltd.).
  • Exhibit 3.3
    • Table representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 3.4
    • Line chart representing Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 3.5
    • Bar chart representing Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 3.6
    • Table representing the Total Addressable Market, TAM forecast by 2021 (for the 2011- 2021 period), for nanotechnology in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 3.7
    • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 3.8
    • Bar chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011- 2021 period), for nanotechnology in drug delivery, without segmentation, source: Cientifica (all figures US$ Million Dollars).

Chapter Four: Nanotechnology in Drug Delivery

  • Exhibit 4.1
    • Typical Image of Colloidal Gold Nanoparticles [1].
  • Exhibit 4.2
    • Examples of nanocarriers used for targeting cancer. (A) A whole range of delivery agents are possible but the main components typically include a nanocarrier, a targeting moiety conjugated to the nanocarrier and a cargo (such as the desired chemotherapeutic drugs); (B) Schematic diagram of the drug conjugation and entrapment processes. The chemotherapeutics could be bound to the nanocarrier, as in the use of polymer - drug conjugates, dendrimers and some particulate carriers or they could be entrapped inside the nanocarrier [3].
  • Exhibit 4.3
    • Schematic representation of different mechanisms of drug delivery to tumours using nanocarriers. Polymeric nanoparticles are shown as representative nanocarriers (circles).
    • Passive tissue targeting is achieved by extravasation of nanoparticles through increased permeability of the tumour vasculature and ineffective lymphatic drainage (EPR effect).
    • Active cellular targeting (inset) can be achieved by functionalizing the surface of nanocarriers with ligands that induce cell-specific recognition and binding. The
    • nanocarriers can (a) release their contents in close proximity to the target tumour cells; (b) attach to the membrane of the tumour cell and play the role of an extracellular sustainedrelease drug depot; or (c) internalize into the tumour cell [3].
  • Exhibit 4.4
    • Advantages and disadvantages of different methods for the production of drug nanocrystals [6].
  • Exhibit 4.5
    • Representative examples of clinically approved nanocarrier-based drug formulations with presence on the market [4].
  • Exhibit 4.6
    • Some examples of nano-based platforms and their current stage of development for use in cancer therapy [3].
  • Exhibit 4.7
    • Representative examples of clinically approved nanocrystals-based drug formulations with presence on the market [6]
  • Exhibit 4.8
    • Table representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, all countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.9
    • 3-D pie chart representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, by world regions and countries, source: Cientifica (all figures in percentage).
  • Exhibit 4.10
    • Horizontal bar graph representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, by world regions and countries, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.11
    • Line chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, by world regions and countries, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.12
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000- 2010), for nanotechnology in drug delivery, by world regions and countries, source:
    • Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.13
    • 3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, by world regions and countries, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.14
    • 3-D pie chart representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, all world regions and countries studied, source: Cientifica (all figures in percentage).
  • Exhibit 4.15
    • Horizontal bar graph representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, all world regions and countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.16
    • 3-D pie chart representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all figures in percentage).
  • Exhibit 4.17
    • Horizontal bar graph representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.18
    • Line chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all
    • figures US$ Million Dollars).
  • Exhibit 4.19
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000- 2010), for nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.20
    • 3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.21
    • 3-D pie chart representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures in
    • percentage).
  • Exhibit 4.22
    • Horizontal bar graph representing the Total Addressable Market, TAM In 2010, for nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.23
    • Line chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.24
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000- 2010), for nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.25
    • 3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.26
    • Table representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, all most relevant key technologies, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.27
    • 3-D pie chart representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures in percentage).
  • Exhibit 4.28
    • Horizontal bar graph representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.29
    • Line chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures
    • US$ Million Dollars).
  • Exhibit 4.30
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000- 2010) , for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.31
    • 3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010) , for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.32
    • 3-D pie chart representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures in
    • percentage).
  • Exhibit 4.33
    • Horizontal bar graph representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.34
    • Line chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.35
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000- 2010) , for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.36
    • 3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010) , for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.37
    • 3-D pie chart representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source: Cientifica (all figures in percentage).
  • Exhibit 4.38
    • Line chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.39
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM (2000- 2010) , for nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.40
    • 3-D stacked area chart representing the Total Addressable Market, TAM (2000-2010) , for nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.41
    • 3-D pie chart representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, impact of drug solubility and drug bioavailability, source: Cientifica (all figures in percentage).
  • Exhibit 4.42
    • Line chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, impact of drug solubility and drug bioavailability, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.43
    • 3-D pie chart representing the Total Addressable Market, TAM in 2010, for nanotechnology in drug delivery, impact of targeted delivery, source: Cientifica (all figures in percentage).
  • Exhibit 4.44
    • Line chart representing the Total Addressable Market, TAM (2000-2010), for nanotechnology in drug delivery, impact of targeted delivery, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.45
    • In vivo effects of nanocrystals-based drug formulations [6].
  • Exhibit 4.46
    • Table representing the Total Addressable Market, TAM forecast by 2021 (for the 2011- 2021 period), for nanotechnology in drug delivery, by world regions / countries, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.47
    • 3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, by world regions, source: Cientifica (all figures in percentage).
  • Exhibit 4.48
    • Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, by world regions, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.49
    • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, by world regions, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.50
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, by world regions, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.51
    • 3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, by world regions, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.52
    • 3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, by all world regions / countries studied, source: Cientifica (all figures in percentage).
  • Exhibit 4.53
    • Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, by all world regions / countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.54
    • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, by all world regions / countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.55
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, by all world regions / countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.56
    • 3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, by all world regions / countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.57
    • 3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all figures in percentage).
  • Exhibit 4.58
    • Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.59
    • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.60
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, European Union countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.61
    • 3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, European Union
    • countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.62
    • 3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures in percentage).
  • Exhibit 4.63
    • Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.64
    • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.65
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.66
    • 3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, Asian countries studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.67
    • Table representing the Total Addressable Market, TAM forecast by 2021 (for the 2011- 2021 period), for nanotechnology in drug delivery, all most relevant key technologies, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.68
    • 3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures in percentage).
  • Exhibit 4.69
    • Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures in percentage).
  • Exhibit 4.70
    • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, all key technologies studied,
    • source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.71
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, all key
    • technologies studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.72
    • 3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, all key technologies studied, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.73
    • 3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures in percentage).
  • Exhibit 4.74
    • Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.75
    • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.76
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.77
    • 3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers as a whole, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.78
    • 3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source: Cientifica (all figures in percentage).
  • Exhibit 4.79
    • Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source:
    • Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.80
    • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers versus drug
    • nanocrystals, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.81
    • 3-D stacked vertical bar graph representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.82
    • 3-D stacked area chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, nanocarriers versus drug nanocrystals, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.83
    • 3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, impact of drug solubility and drug bioavailability, source: Cientifica (all figures in percentage).
  • Exhibit 4.84
    • Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, impact of drug solubility and drug bioavailability, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.85
    • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, impact of drug solubility and drug bioavailability, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.86
    • 3-D pie chart representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, impact of targeted delivery, source: Cientifica (all figures in percentage).
  • Exhibit 4.87
    • Horizontal bar graph representing the Total Addressable Market, TAM forecast in 2021, for nanotechnology in drug delivery, impact of targeted delivery, source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.88
    • Line chart representing the Total Addressable Market, TAM forecast by 2021 (for the 2011-2021 period), for nanotechnology in drug delivery, impact of targeted delivery,
    • source: Cientifica (all figures US$ Million Dollars).
  • Exhibit 4.89
    • SWOT analysis to evaluate the strengths, weaknesses, opportunities and threats involved in nanotechnology in drug delivery In the scope of the technology adoption roadmap (during the 2011-2021 period).

Appendix

  • Exhibit A.1
    • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: North America; country: USA. Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.2
    • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: European Union; country: Germany. Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.3
    • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: European Union; country: France. Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.4
    • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: European Union; country: UK. Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.5
    • Table of the organizations with publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. Country: Russian Federation. Organizations are ordered alphabetically (increasing order).
  • Exhibit A.6
    • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: Asia; country: India. Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.7
    • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: Asia; country: India. Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.8
    • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: Asia; country: Japan. Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.9
    • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: Asia; country: P R China. Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.10
    • Table of the top 20 organizations showing the highest publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. World Region: Asia; country: South Korea (Republic of Korea). Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
  • Exhibit A.11
    • Table of the organizations with publishing activity in PubMed periodicals (2000-2010), based on PubMed, for Nanotechnology in Drug Delivery. Asia; country: Taiwan. Organizations are ordered first by descending order of total articles published and then ordered alphabetically (increasing order), if applicable.
Back to Top